Fate Therapeutics Inc.

Fate Therapeutics Inc. company information, Employees & Contact Information

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Company Details

Employees
242
Founded
-
Address
12278 Scripps Summit Dr, San Diego,california 92131,united States
Phone
8588751802
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Fate Therapeutics Inc. employee's phone or email?

Fate Therapeutics Inc. Questions

News

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewswire

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector Seeking Alpha

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer - GlobeNewswire

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer GlobeNewswire

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - Yahoo Finance

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress Yahoo Finance

Clinical trial: Solid Tumors, (NCT06241456) - CRISPR Medicine News

Clinical trial: Solid Tumors, (NCT06241456) CRISPR Medicine News

Fate Therapeutics to Present Clinical and Preclinical Data on Off-the-Shelf iPSC-Derived Cell Therapies at EULAR 2025 - Nasdaq

Fate Therapeutics to Present Clinical and Preclinical Data on Off-the-Shelf iPSC-Derived Cell Therapies at EULAR 2025 Nasdaq

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options Seeking Alpha

Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates GlobeNewswire

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates GlobeNewswire

Fate Therapeutics Receives Regenerative Medicine Advanced - GlobeNewswire

Fate Therapeutics Receives Regenerative Medicine Advanced GlobeNewswire

Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire

Fate Therapeutics Announces Phase 1 Data Presentation of GlobeNewswire

Fate Therapeutics Announces Five Presentations on - GlobeNewswire

Fate Therapeutics Announces Five Presentations on GlobeNewswire

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates GlobeNewswire

Fate Therapeutics Announces Leadership Transition - GlobeNewswire

Fate Therapeutics Announces Leadership Transition GlobeNewswire

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence Yahoo Finance

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement - GlobeNewswire

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement GlobeNewswire

Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®

Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus CGTLive®

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 Nasdaq

Fate Therapeutics Announces Presentation of FT522 - GlobeNewswire

Fate Therapeutics Announces Presentation of FT522 GlobeNewswire

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - Stock Titan

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates Stock Titan

Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service - Quantisnow

Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service Quantisnow

Changing the fate of cellular immunotherapy - Nature

Changing the fate of cellular immunotherapy Nature

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients Stock Titan

IND Update: Gene-Edited CAR Natural Killer Cell Therapy for Solid Tumours - CRISPR Medicine News

IND Update: Gene-Edited CAR Natural Killer Cell Therapy for Solid Tumours CRISPR Medicine News

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 - Precedence Research

Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034 Precedence Research

Induced Pluripotent Stem Cell (iPSC) Therapy Market Size, Report by 2034 - Precedence Research

Induced Pluripotent Stem Cell (iPSC) Therapy Market Size, Report by 2034 Precedence Research

FATE Stock Price and Chart — NASDAQ:FATE - TradingView

FATE Stock Price and Chart — NASDAQ:FATE TradingView

Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize - Pharmaceutical Executive

Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize Pharmaceutical Executive

Top 10 Regenerative Medicine Companies | Innovative and Rapidly Advancing - Market.us Media

Top 10 Regenerative Medicine Companies | Innovative and Rapidly Advancing Market.us Media

Gene-Editing Clinical Trial Update - CRISPR Medicine News

Gene-Editing Clinical Trial Update CRISPR Medicine News

Fate Therapeutics and ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies - BioInformant

Fate Therapeutics and ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies BioInformant

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies - Stem Cell Research & Therapy

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies Stem Cell Research & Therapy

Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress - GlobeNewswire

Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire

Fate Therapeutics (FATE) Stock Price, News & Analysis - MarketBeat

Fate Therapeutics (FATE) Stock Price, News & Analysis MarketBeat

Top Fate Therapeutics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant